●药闻快报▲关注药财社聚焦医药界▲1海思科1类新药HSK31679拟纳入突破性治疗品种3月4日,中国国家药品监督管理局药品审评中心(CDE)官网显示,海思科医药集团自主研发的1类创新药HSK31679片正式申请纳入突破性治疗品种,旨在用于治疗非酒精性脂肪肝炎(MASH/NASH)。该药作为一种高选择性甲状腺激素β受体激动剂,通过调控多种肝脏代谢通路发挥治疗潜力。公开资料显示,HSK31679在此前...
Source Link●药闻快报▲关注药财社聚焦医药界▲1海思科1类新药HSK31679拟纳入突破性治疗品种3月4日,中国国家药品监督管理局药品审评中心(CDE)官网显示,海思科医药集团自主研发的1类创新药HSK31679片正式申请纳入突破性治疗品种,旨在用于治疗非酒精性脂肪肝炎(MASH/NASH)。该药作为一种高选择性甲状腺激素β受体激动剂,通过调控多种肝脏代谢通路发挥治疗潜力。公开资料显示,HSK31679在此前...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.